CAMP CAMP4 Therapeutics Corp.

  1. Stocks
  2. Healthcare
  3. NASDAQ: CAMP

Price (delayed)

$4.37

Market cap

$226.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.36

Enterprise value

$129.1M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 20

We are a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a ...

Highlights
CAMP4 Therapeutics's revenue has soared by 161% YoY and by 12% from the previous quarter
The gross profit has soared by 161% YoY and by 12% from the previous quarter
The company's EPS has shrunk by 116% YoY but it rose by 11% QoQ
CAMP's debt has plunged by 73% YoY but it is up by 7% from the previous quarter
The net income has shrunk by 67% YoY and by 7% QoQ
The equity is down by 40% year-on-year and by 35% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.camp4tx.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of CAMP

CAMP stock price

How has the CAMP4 Therapeutics stock price performed over time
Intraday
4.8%
1 week
-2.67%
1 month
13.21%
1 year
130%
YTD
-28.71%
QTD
-0.91%

Financial performance

How have CAMP4 Therapeutics's revenue and profit performed over time
Revenue
$3.93M
Gross profit
$3.93M
Operating income
-$52.53M
Net income
-$86.3M
Gross margin
100%
Net margin
-2,193.7%
CAMP4 Therapeutics's revenue has soared by 161% YoY and by 12% from the previous quarter
The gross profit has soared by 161% YoY and by 12% from the previous quarter
The net income has shrunk by 67% YoY and by 7% QoQ
CAMP's operating margin has surged by 62% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does CAMP's price correlate with its fundamentals

Growth

What is CAMP4 Therapeutics's growth rate over time

Valuation

What is CAMP4 Therapeutics stock price valuation
P/E
N/A
P/B
7.34
P/S
64.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.82
The company's EPS has shrunk by 116% YoY but it rose by 11% QoQ
CAMP's price to book (P/B) is 84% more than its last 4 quarters average of 3.8
The equity is down by 40% year-on-year and by 35% since the previous quarter
CAMP4 Therapeutics's revenue has soared by 161% YoY and by 12% from the previous quarter
CAMP's price to sales (P/S) is 64% higher than its last 4 quarters average of 37.4

Efficiency

How efficient is CAMP4 Therapeutics business performance
The company's return on sales rose by 36% YoY and by 4.6% QoQ
The ROE has contracted by 20% from the previous quarter
The return on assets has increased by 11% year-on-year and by 5% since the previous quarter

Dividends

What is CAMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CAMP.

Financial health

How did CAMP4 Therapeutics financials performed over time
CAMP4 Therapeutics's total assets is 41% higher than its total liabilities
CAMP4 Therapeutics's total assets has surged by 68% YoY but it has decreased by 10% QoQ
The company's quick ratio fell by 24% YoY and by 16% QoQ
CAMP's debt is 93% less than its equity
The company's debt to equity has surged by 75% QoQ but it has shrunk by 53% YoY
CAMP's debt has plunged by 73% YoY but it is up by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.